On August 10, INSILICO rose 9.6% in regular trading, trading at 50.9 HKD/share, with turnover of 92.32 million HKD. The rally was driven by dual catalysts: the NMPA clinical trial approval of its blood-brain barrier penetrating NLRP3 inhibitor and JPMorgan's initiation of coverage.

Specifically, INSILICO and Hengtai Bio's co-developed oral NLRP3 inhibitor ISM8969/HT-001 received NMPA approval for clinical trials targeting Parkinson's disease. Unlike other peripherally-restricted NLRP3 inhibitors in clinical development, ISM8969/HT-001 can penetrate the blood-brain barrier and enter the central nervous system, offering therapeutic potential for neuroinflammation-related diseases. The clinical trial will evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy in Parkinson's patients.

Additionally, JPMorgan initiated coverage on INSILICO with an \"Overweight\" rating and a target price of 71 HKD, implying approximately 39% upside from the current level. This follows the company's H1 profit alert projecting revenue of USD 103-107 million (up ~275% YoY) and net profit of USD 33.5-39.5 million, marking a turnaround from a loss of USD 19.2 million in the prior year period.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)